Vasoactive exposures during pregnancy and risk of microtia
- PMID: 23180593
- PMCID: PMC4521508
- DOI: 10.1002/bdra.23101
Vasoactive exposures during pregnancy and risk of microtia
Abstract
Background: Little is known about the etiology of nonsyndromic microtia. This study investigated the hypothesis that microtia is caused by vascular disruption.
Methods: The study analyzed data from the population-based National Birth Defects Prevention Study (NBDPS) for deliveries between 1997 and 2005. Four hundred eleven nonsyndromic cases of microtia, with or without additional defects, were compared to 6560 nonmalformed infants with respect to maternal exposures to vasoactive medications and smoking during the periconceptional period and conditions that have previously been associated with vascular events (multiple gestation, maternal history of type 1, type 2, or gestational diabetes, and hypertension). Odds ratios (ORs) were estimated with multivariable models, controlling for the effects of race/ethnicity, education, periconceptional folic acid use, and study center.
Results: Risk estimates for vasoactive medications and smoking were not meaningfully increased. Maternal type 1/2 diabetes was diagnosed before or during the index pregnancy in 4% and 1% of cases, respectively, compared to 1% and 0.05% of controls; the adjusted OR for these two groups combined was 7.2 (95% confidence interval [CI], 3.9-13.1). Gestational diabetes was observed for 9% of cases and 6% of controls; the OR was moderately elevated (OR, 1.4; 95% CI, 0.9-2.0). ORs were also increased for multiple gestations (OR, 2.5; 95% CI, 1.5-4.2) and pre-existing hypertension (OR, 1.6; 95% CI, 1.0-2.5).
Conclusions: Because ORs were only elevated for diabetes and not for vasoactive exposures or other potential vascular events, findings suggest that some microtia occurrences may be part of the diabetic embryopathy rather than manifestations of vascular disruption. Birth Defects Research (Part A), 2013. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.
Conflict of interest statement
Dr. Werler serves on the advisory board of studies that evaluate the effects of medications taken in pregnancy for rheumatoid arthritis. It is possible that the manufacturers of these medications also make drugs that were examined in this article. Dr. Werler does not track manufacturer's product lines. Therefore, we believe there is no conflict of interest. Dr. Mitchell owns Johnson & Johnson stock valued at less than $20,000, and the company makes a number of the products under study; the company had no involvement in or knowledge of this analysis. Dr. Moore and Ms. Van Bennekom report no conflicts of interest.
References
-
- Alasti F, Van Camp G. Genetics of microtia and associated syndromes. J Med Genet. 2009;46:361–369. - PubMed
-
- Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy. Chest. 2004;126(3suppl):627S–644S. - PubMed
-
- Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics. 1990;85:1–9. - PubMed
-
- Canfield MA, Langlois PH, Nguyen LM, Scheuerle AE. Epidemiologic features and clinical subgroups of anotia/microtia in Texas. Birth Defects Res A Clin Mol Teratol. 2009;85:905–913. - PubMed
-
- Castilla EE, Lopez–Camelo JS, Campaña H. Altitude as a risk factor for congenital anomalies. Am J Med Genet. 1999;86:9–14. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical